Newgenivf Group Limited · NASDAQ:NIVF
Newgenivf — SPAC Merger (July 2023)
31 slides from Newgenivf's SPAC merger presentation, Jul 14, 2023
Slide 1: Company Investor Presentation July 2023
Company Investor Presentation July 2023
Slide 2: Disclaimer
2 Disclaimer This confidential presentation (the “Presentation”) is being delivered to a limited number of parties for discussion purposes on ly. Any reproduction of distribution of this Presentation, in whole or in part, or the disclosure of its contents, without the prior consent of A SPAC I Acqui
Slide 3: Disclaimer (Continued)
3 Disclaimer (Continued) Trademarks This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the propert y o f their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in th
Slide 4: Agenda
4 01 Executive Summary 02 Industry Outlook 03 Investment Highlights and Company Strategy 04 Business Operations 05 Company Financials 06 Appendix & Risk Factors
Slide 5: Executive Summary
( 1 ) Executive Summary
Slide 6: Transaction Overview
6 Transaction Overview Background Pro Forma Ownership & Valuation Alignment of Equity Interest Governance NewGenIvf Limited (“ NewGenI vf ”) entered into a merger agreement with A SPAC I Acquisition Corp. (“ASCA”) on February 15, 2023 NewGenIvf management and shareholders to own 45% at close of
Slide 7: Company Overview
7 Company Overview Stable Profitability During COVID Despite Challenging Environment Legally - Qualified & Licensed Provision of IVF & Surrogacy Services 3 Clinics at Favourable Locations with Multi - lingual & Multi - cultural Staff Fast Growing Market Size With Significant Unmet Demand For ARS Com
Slide 8: Industry Overview
( 2 ) Industry Overview
Slide 9: ARS: Rising Demand With Significant Growth Opportunity
9 2.1 ARS: Rising Demand With Significant Growth Opportunity Note : (1) In 2022 Source: F rom research conducted by China Insights Consultancy (“CIC”) Shifting Social and Cultural View towards ARS Continued de - stigmatization of infertility drive stronger demand for fertility treatment services
Slide 10: ARS: Expanding Market Size And Unfulfilled Market Demand
10 2.2 ARS: Expanding Market Size And Unfulfilled Market Demand 213+ million Infertile couples in Asia - Pacific in 2022 US$37.4 bn Potential Asia Fertility Market in 2030 Rising ARS Users in Recent Years 98.9% Untreated Infertile Couples 1 China (000’ cases) Japan (000’ cases) 136.8 184.9 2017 2022
Slide 11: Investment Highlights and Company Strategy
1 Investment Highlights and Company Strategy 3
Slide 12: Investment Highlights
12 3.1 Investment Highlights Solution Provider Offering Comprehensive Fertility Treatment Services • IVF services in Thailand and Cambodia • Greater affordability 1 Attractive Market with Significant Demand and Fast Growth Exclusively Licensed Use of “ MicroSort 2 ” & Access to Latest Fertility Tech
Slide 13: Company Strategy
13 3.2 Company Strategy Offer Broad Fertility Services for Fertility Tourists across Asia - Pacific Integrate fertility services with travel - related offerings to enhance customer’s experience Aim to capture a share of the growing market for fertility tourism in Asia - Pacific Continue to Inves
Slide 14: Business Operations
¢ 4 } Business Operations
Slide 15: Corporate History
15 4.1 Corporate History 2010 IVF agency: Sending patients to Thailand 2014 Register IVF Center First Firtility PGS Center in Bangkok Thailand 2015 Register First Fertility Phnom Penh Limited in Phnom Penh Cambodia 2019 Register First Fertility Bishkek in Kyrgyzstan First Fertility PGS Cen
Slide 16: Provision of A Broad Spectrum of ARS Products & Services
16 Surrogacy Services Maternity care services, including body check, provision of vitamins, supplements & medicines Birth certificate application Infant’s passport & visa services Full - Cycle Services (IVF) Consultation, tests & treatment plan design Synthetic hormones injection & regular
Slide 17: Business Overview
17 4.3 Business Overview 10+ Years of Experience 3,500+ Cycles of IVF Completed 1 Sales Office + 3 Clinics 60+ Employees First Fertility PGS Center Bangkok, Thailand IVF Services First Fertility Phonom Penh, Cambodia IVF Services Sales & Marketing Office Hong Kong Sales & Admin First Fertility Bishk
Slide 18: Business Operations
18 4.4 Business Operations Continuing Effective Marketing • Referrals • Social media promotions and marketing initiatives • Strategic investments & partnerships Experienced Physicians & Medical Professionals • Medical professionals • Nursing professionals • Medical technology professionals Licenses
Slide 19: Exclusive License to Use MicroSort in Thailand & Cambodia
19 MicroSort Technology Microsort Technology Traditional Method Microsort Technology 4.5 Exclusive License to Use MicroSort in Thailand & Cambodia VS Process of MICROSORT A p re - conception gender selection technology , which means: Gender selection is conducted post - conception Conceive Filter Se
Slide 20: Surrogacy Procedure and Timeline
20 4.6 Surrogacy Procedure and Timeline STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 Frozen Embryo Transfer • Arrange for the surrogate mother (who has already been tested and qualified) for embryo transfer; all surrogate mothers will be under the care of First Fertility Bishkek . Pregnancy Test • If t
Slide 21: Management Team
21 4.7 Management Team Photo to come Mr. Siu Wing Fung, Alfred Founder, Chairman of the Board of Directors Ms. Fong Hei Yue, Tina Director, Co - Founder, Chief Marketing Officer • Has served as the Chairman of the Board and CEO of NewGenIvf since 2019 • Served as the director of First Fertility PGS
Slide 22: Company Financials
¢ 5 ) Company Financials
Slide 23: Robust Growth in Revenue With Stable Profit Margin
23 5.1 Robust Growth in Revenue With Stable Profit Margin Robust Revenue Growth (in US$’000) Revenue Breakdown by Geographic Regions (in US$’000) 693.9 Thailand 313.7 Cambodia 3,110.5 Kyrgyzstan 2021 505.6 Thailand 377.6 Cambodia 5,061.0 Kyrgyzstan 2022 Gross Profit and Gross Profit Margin (in US$’0
Slide 24: Effective Expense Control and Rising Profitability
24 5.2 Effective Expense Control and Rising Profitability Significant Rise in Net Income Attributable to Shareholders and EPS (in US$’000 for Net Income, in US$ for EPS) 199.5 698.7 4.8% 11.8% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 18.0% 20.0% 0 100 200 300 400 500 600 700 800 2021 2022 Ne
Slide 25: Appendix
Appendix
Slide 26: Appendix 1: IVF Procedure
Appendix 1: IVF Procedure Follow Up Estradiol (E2) Period Fly to | Injection | Injection | Injection Day1 | Bangkok | Day 1 Day 2 Day 3 Follow Up Hormones & TVS Injection | Injection | Injection | Injection | Injection | Injection | Injection Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Follow Up Horm
Slide 27: Risk Factors
Risk Factors
Slide 28: Risk Factors
28 Risk Factors References in the summary below to “ASCA” refer to A SPAC I Acquisition Corp., which will reincorporate to the British Virgin Is lands by merging with and into A SPAC I Mini Acquisition Corp. (“ PubCo ”), with PubCo remaining as the surviving publicly traded entity. The combined comp
Slide 29: Risk Factors (Continued)
29 Risk Factors (Continued) Risks Related to NewGenIvf’s Relationships with Third Parties • NewGenIvf’s business depends on its ability to maintain its network of high - quality fertility specialists and other healthcare providers. I f NewGenIvf is unable to do so, its future growth would be limited
Slide 30: Q&A
Q&A
Slide 31: THANK YOU
THANK YOU